Form D · Biotechnology
Kylin Therapeutics Inc
West Lafayette, IN · CIK 0001418644
Offering snapshot reported Nov 23, 2009 · SEC filing
- Reported sold
- $57.9K Offering amount: $2M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $100K Reported outside-investor minimum
- First sale
- Nov 9, 2009 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 23, 2009 | Initial | $57,896 | No comparison | 2 | SEC filing |
| Jan 8, 2009 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Nov 13, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-111031
Source: Form D, filed Nov 23, 2009. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| J. Eric Davis | Director, Executive |
| Christopher Meldrum | Director, Executive |
| Homer Pearce | Director |
| Joseph Trebley | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
3000 Kent Avenue
West Lafayette, IN, 47906
West Lafayette, IN, 47906